Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site New Routes to Targeted Therapies

被引:182
|
作者
Ross, Jeffrey S. [1 ,2 ]
Wang, Kai [1 ]
Gay, Laurie [1 ]
Otto, Geoff A. [1 ]
White, Emily [1 ]
Iwanik, Kiel [1 ]
Palmer, Gary [1 ]
Yelensky, Roman [1 ]
Lipson, Doron M. [1 ]
Chmielecki, Juliann [1 ]
Erlich, Rachel L. [1 ]
Rankin, Andrew N. [1 ]
Ali, Siraj M. [1 ]
Elvin, Julia A. [1 ]
Morosini, Deborah [1 ]
Miller, Vincent A. [1 ]
Stephens, Philip J. [1 ]
机构
[1] Medicine Inc, Cambridge, MA USA
[2] Albany Med Coll, Dept Pathol & Lab Med, Albany, NY 12208 USA
关键词
LUNG-CANCER; GENE MUTATION; DIAGNOSIS; ORIGIN; TISSUE; EXPRESSION; AMPLIFICATION; CRIZOTINIB; MANAGEMENT; RECEPTOR;
D O I
10.1001/jamaoncol.2014.216
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
IMPORTANCE For carcinoma of unknown primary site (CUP), determining the primary tumor site may be uninformative and often does not improve outcome. OBJECTIVE To discover opportunities for targeted therapies in patients with CUP not currently searched for in routine practice. DESIGN. SETTING, AND PARTICIPANTS Comprehensive genomic profiling on 200 CUP formalin-fixed paraffin-embedded specimens (mean, 756x coverage) using the hybrid-capture-based FoundationOne assay at academic and community oncology clinics. MAIN OUTCOMES AND MEASURES Presence of targetable genomic alterations (GAs) in CUP and responses to targeted therapies. RESULTS There were 125 adenocarcinomas of unknown primary site (ACUPs) and 75 carcinomas of unknown primary site without features of adenocarcinoma (non-ACUPs). At least 1 GA was found in 192 (96%) of CUP specimens, with a mean (SD) of 4.2 (2.8) GAs per tumor. The most frequent GAs were in TP53 (110 [55%]), KRAS (40 [20%]), CDKN2A (37 [19%]), MYC (23 [12%]), ARID1A (21 [11%]), MCLI (19 [10%]), PIK3CA (17 [9%]), ERBB2 (16 [8%]), PTEN (14 [7%]), EGFR (12 [6%]), SMAD4 (13 [7%]), STKI1 (13 [7%]), SMARCA4 (12 [6%]), RBI (12 [6%]), RICTOR (12 [6%]), MLL2 (12 [6%]), BRAF (11[6 %]), and BRCA2 (11[6 %]). One or more potentially targetable GAs were identified in 169 of 200 (85%) CUP specimens. Mutations or amplifications of ERBB2 were more frequent in ACUPs (13 [10%]) than in non-ACUPs (3 [4%]). Alterations of EGFR (10 [8%] vs 2 [3%]) and BRAF (8 [6%] vs 3 [4%]) were more common in ACUPs than in non-ACUPs. Strikingly, clinically relevant alterations in the receptor tyrosine kinase (RTK)/Ras signaling pathway including alterations in ALK, ARAF, BRAF, EGFR, FGFRI, FGFR2, KIT, KRAS, MAP2K, MET, NF1, NF2, NRAS, RAF1, RET, and ROSI were found in 90 (72%) ACUPs but in only 29 (39%) non-ACUPs (P<. 001). CONCLUSIONS AND RELEVANCE Almost all CUP samples harbored at least 1 clinically relevant GA with potential to influence and personalize therapy. The ACUP tumors were more frequently driven by GAs in the highly druggable RTK/Ras/mitogen-activated protein kinase (MAPK) signaling pathway than the non-ACUP tumors. Comprehensive genomic profiling can identify novel treatment paradigms to address the limited options and poor prognoses of patients with CUR
引用
收藏
页码:40 / 49
页数:10
相关论文
共 50 条
  • [31] Comprehensive Genomic Profiling of Relapsed and Metastatic Adenoid Cystic Carcinomas (ACC) by Next Generation Sequencing (NGS) Reveals New Routes to Targeted Therapies
    Rand, J. V.
    Sheehan, C. E.
    Jennings, T. A.
    Al-Rohil, R. N.
    Otto, G.
    Curran, J.
    Palmer, G.
    Downing, S.
    Yelensky, R.
    Lipson, D.
    Balasubramanian, S.
    Garcia, L.
    Mahoney, K.
    Miller, V.
    Stephens, P.
    Ross, J. S.
    LABORATORY INVESTIGATION, 2013, 93 : 311A - 312A
  • [32] Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies
    Ross, J. S.
    Ali, S. M.
    Wang, K.
    Palmer, G.
    Yelensky, R.
    Lipson, D.
    Miller, V. A.
    Zajchowski, D.
    Shawver, L. K.
    Stephens, P. J.
    GYNECOLOGIC ONCOLOGY, 2013, 130 (03) : 554 - 559
  • [33] Targeted Genomic Profiling of Melanoma of Unknown Primary Site Reveals Mutational Profile Similar to Cutaneous Melanoma
    DeSimone, Mia
    Mahadevan, Navin
    Davineni, Phani
    Murphy, George
    Lian, Christine
    Dong, Fei
    MODERN PATHOLOGY, 2019, 32
  • [34] Targeted Genomic Profiling of Melanoma of Unknown Primary Site Reveals Mutational Profile Similar to Cutaneous Melanoma
    DeSimone, Mia
    Mahadevan, Navin
    Davineni, Phani
    Murphy, George
    Lian, Christine
    Dong, Fei
    LABORATORY INVESTIGATION, 2019, 99
  • [35] Carcinoma of unknown primary (CUP): The role of tumor genomic profiling
    Park, C.
    Georlette, D.
    Korn, W. M.
    Xiu, J.
    Babiker, H.
    Barata, P. M. Coelho
    Sohal, D.
    ANNALS OF ONCOLOGY, 2021, 32 : S926 - S926
  • [36] Genomic profiling for unfavorable carcinoma of unknown primary patients.
    Lu, Hsueh-Ju
    Liu, Hsuan
    Hang, Jen-Fan
    Chao, Yee
    Chen, Ming-Huang
    Liu, Chun-Yu
    Huang, Chi-Ying F.
    Chang, Mu-Hsin
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [37] Comprehensive Genomic Profiling of Orbital and Ocular Adnexal Lymphomas Identifies Frequent Alterations in MYD88 and Chromatin Modifiers: New Routes to Targeted Therapies
    Rao, Rawesh C.
    Cani, Andi
    Soliman, Moaaz
    Hovelson, Daniel H.
    Liu, Chia-Jen
    McDaniel, Andrew S.
    Haller, Michaela J.
    Bratley, Larred
    Rahrig, Samantha
    Briceno, Cesar A.
    Tomlins, Scott A.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)
  • [38] Comprehensive genomic profiling of orbital and ocular adnexal lymphomas identifies frequent alterations in MYD88 and chromatin modifiers: new routes to targeted therapies
    Cani, Andi K.
    Soliman, Moaaz
    Hovelson, Daniel H.
    Liu, Chia-Jen
    McDaniel, Andrew S.
    Haller, Michaela J.
    Bratley, Jarred V.
    Rahrig, Samantha E.
    Li, Qiang
    Briceno, Cesar A.
    Tomlins, Scott A.
    Rao, Rajesh C.
    MODERN PATHOLOGY, 2016, 29 (07) : 685 - 697
  • [39] Genomic Drivers of Pleural Malignant Mesothelioma Determined By Comprehensive Genomic Profiling: Opportunities for Targeted Therapies
    Voronel, Olga
    Wang, Kai
    He, Jie
    Seiwert, Tanguy
    Nozad, Sahar
    Sheehan, Christine
    Elvin, Julia
    Ali, Siraj
    Lipson, Doron
    Yelensky, Roman
    Chmielecki, Juliann
    Miller, Vincent
    Husain, Aliya
    Stephens, Philip
    Ross, Jeffrey
    MODERN PATHOLOGY, 2015, 28 : 491A - 491A
  • [40] Genomic Drivers of Pleural Malignant Mesothelioma Determined By Comprehensive Genomic Profiling: Opportunities for Targeted Therapies
    Voronel, Olga
    Wang, Kai
    He, Jie
    Seiwert, Tanguy
    Nozad, Sahar
    Sheehan, Christine
    Elvin, Julia
    Ali, Siraj
    Lipson, Doron
    Yelensky, Roman
    Chmielecki, Juliann
    Miller, Vincent
    Husain, Aliya
    Stephens, Philip
    Ross, Jeffrey
    LABORATORY INVESTIGATION, 2015, 95 : 491A - 491A